3.1.10.2. mycophenolates (mpa). mycophenolates, mmf ec-mps, based mycophenolic acid, inhibits inosine monophosphate dehydrogenase (impdh) [285-289]. rate-limiting step synthesis guanosine monophosphate de novo purine pathway. function proliferation lymphocytes dependent de novo purine nucleotide synthesis compared cell types, impdh inhibitors may provide specific lymphocyte-targeted immunosuppression. co-administration mycophenolate prednisolone cni resulted profound reduction biopsy-proven rejections [243,246,285-289]. mycophenolic acid nephrotoxic; however, inhibits bone marrow function may cause cmv infections gastrointestinal side effects, particularly diarrhoea [243,246,285-289]. also higher incidence polyoma nephropathy, especially mycophenolate combined tacrolimus . mpa formulations equally effective almost identical safety profile [241,280,283,285-288], though prospective studies suggest better gastrointestinal side-effect profile ec-mps patients suffered mmf-related gastrointestinal complaints, although firm evidence prospective randomised studies lacking [285-289,291]. mycophenolic acid recommended guidelines . standard doses combination cyclosporine mmf 1 g ec-mps 720 mg twice daily, although higher initial doses suggested [243,244,285-289]. despite frequent use tacrolimus, insufficient evidence support optimal dosage combination . tacrolimus influence mpa exposure leads approximately 30% higher mpa exposure compared cyclosporine. transplant centres use starting dose cyclosporine-treated patients, however dose reductions frequent, especially gastrointestinal side effects. weak evidence suggests mpa dose reductions associated inferior outcomes, especially cyclosporine treated patients [286-288,293,294]. due high incidence side effects, centres perform protocol-driven mpa dose reduction tacrolimus treated patients . regular monitoring polyoma (bk virus) recommended patients given mpa combined tacrolimus . due higher incidence cmv disease mpa , either cmv prophylaxis pre-emptive strategy regular screening cmv viraemia instituted . cytomegalovirus prophylaxis antiviral medications (e.g. valganciclovir) used routinely cmv positive recipients cmv negative recipients cmv positive organ transplants, prophylaxis recently shown reduce cmv disease, cmv-associated mortality solid organ transplant recipients, leads better long-term graft survival kidney allograft recipients. benefit mpa drug monitoring uncertain currently recommended majority patients . maintenance patients, potency mpa used successful steroid withdrawal patients substantial dose reductions nephrotoxic cnis, may lead better renal function [243-246,248,280,298]. although several studies potential cni-free protocols mpa steroids, complete cni avoidance withdrawal first three years associated substantially increased rejection risk even worse outcomes prospective randomised studies . contrast, cni withdrawal mpa steroids appeared safe long-term maintenance patients beyond five years post-transplant resulted improved renal function . summary evidencelethe co-administration mpa prednisolone cni resulted profound reduction biopsy-proven rejections.1both mpa formulations, mmf ec-mps, equally effective almost identical safety profile.1due higher incidence cmv disease mpa either cmv prophylaxis pre-emptive strategy regular screening cmv viraemia instituted1 recommendationstrength ratingadminister mycophenolate part initial immunosuppressive regimen.strong